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Abstract DM235 (sunifiram), a new compound struc-
turally related to piracetam, prevented the amnesia in-
duced by scopolamine (1.5 mg kg–1 i.p.), after intraperi-
toneal (0.001–0.1 mg kg–1) or oral (0.01–0.1 mg kg–1) ad-
ministration, as shown by a passive avoidance test in
mice. The antiamnesic effect of DM235 was comparable
to that of well-known nootropic drugs such as piracetam
(30–100 mg kg–1 i.p.), aniracetam (100 mg kg–1 p.o.) or
rolipram (30 mg kg–1 p.o.). DM235 also prevented
mecamylamine (20 mg kg–1 i.p.)-, baclofen (2 mg kg–1
i.p.)- and clonidine (0.125 mg kg–1 i.p.)-induced amnesia
in the same test. In the Morris water maze test with rats,
scopolamine (0.8 mg kg–1 i.p.) inhibited the reduction of
escape latency in both acquisition and retention/retraining
tests. DM235 (0.1 mg kg–1 i.p.), 20 min before each daily
acquisition training, prevented the scopolamine-induced
memory impairment. DM235 (1 mg kg–1 i.p.) also re-
duced the duration of pentobarbitone-induced hypnosis in
mice without modifying the induction time of hypnosis.
At the highest effective doses, the investigated compound
neither impaired motor coordination (rota-rod test), nor
modified spontaneous motility and inspection activity
(Animex and hole board tests).
These results indicate that DM235, a compound struc-
turally related to piracetam, is a novel nootropic endowed
with the capability to prevent cognitive deficits at very
low doses. Indeed, its potency is about 1,000 times higher
than that of the most active piracetam-like compounds.
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Introduction
The so-called nootropic compounds are a group of phar-
macologically active pyrrolidone derivatives that, in some
respects, occupy a special position in the pharmacology of
the central nervous system. The first pyrrolidone to come
to the attention of clinicians was piracetam. This com-
pound was developed in the late 1960s after pioneering
research by Giurgea who also coined the term “no-
otropic”, meaning enhancement of learning and memory.
Since then, there has been much pharmaceutical interest
in a broad range of indications and in new compounds
(aniracetam, oxiracetam, pramiracetam, nefiracetam, ne-
bracetam, fasoracetam, levetiracetam, etc.). A wide range
of animal models has been used to show improvements in
cognitive function. These tests include maze and spatial
learning, passive avoidance, matching-to-sample, active
avoidance, choice reaction, conditional avoidance and
motor tasks that show definitely positive effects on reten-
tion performance in laboratory animals (Verloes et al.
1988; Sarter 1991; Gouliaev and Senning 1994). No-
otropic drugs also facilitate the transcallosal, interhemi-
spheric transfer of information (Okuyama and Aihara 1988)
and enhance long-term potentiation (LTP) in guinea-pig
hippocampal slices (Satoh et al. 1986; Pugliese et al.
1989). The members of this class show very low toxicity,
have no sedative or stimulatory effects and lack the seri-
ous side effects of psychostimulants (Heise 1987). This
favourable pharmacological profile has stimulated inves-
tigation of the potential antiamnesic activity of nootropics
in human neurodegenerative conditions. Clinical studies
have focused on cognition enhancement and memory im-
provement by nootropic drugs. Some pyrrolidone deriva-
tives, such as piracetam, aniracetam and oxiracetam, ame-
liorate the condition of elderly patients suffering from
mild to moderate mental deterioration (Chouinard et al.
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1983; Maina et al. 1989; Nicholson 1990; Vernon and
Sorkin 1991; Lee and Benfield 1994), of geriatric patients
with cerebrovascular insufficiency (Foltyn et al. 1983), in
Alzheimer’s disease (Senin et al. 1991; Croisile et al.
1993; Parnetti et al. 1997) and are useful in the treatment
of cognitive deficits in early Parkinsonism (Oepen et al.
1985).
Preliminary pharmacological studies have shown that
1,4-diazabicyclo[4.3.0]nonan-9-ones, structurally related
to piracetam, could represent a class of nootropic agents
(Manetti et al. 2000a, 2000b). Among them, the com-
pound DM235 (sunifiram; Fig.1) appears to be endowed
with the best pharmacological profile. The aim of the pre-
sent study was to investigate further the ability of DM235
to ameliorate impaired or unimpaired memory functions
in mice and rats.
Materials and methods
Animals. Male Swiss albino mice (23–30 g) and 70–day-old male
hooded Long-Evans (average body weight 270 g) from Morini
(San Polo d’Enza, Italy) were used. Mice were housed 15 per cage;
the rats were housed individually in stainless-steel cages. For
adaptation, the cages were placed in the experimental room 24 h
prior to tests. Animals always had free access to a standard labora-
tory diet (TRM, Harlan, Padua, Italy) and tap water and were kept
at 23±1°C with a 12-h light/dark cycle (light on at 7 a.m.). All ex-
periments were carried out according to the guidelines of the Eu-
ropean Community Council for experimental animal care. All ex-
periments were performed blind.
Passive-avoidance test. The test was performed according to the
step-through method described by Jarvik and Kopp (1967). The
apparatus consists of a two-compartment acrylic box with a lighted
compartment connected to a darkened one by a guillotine door.
Mice, as soon as they entered the dark compartment, received a
punishing electrical shock (0.3 mA, 1 s). The latency times for en-
tering the dark compartment were measured in the training test and
24 h later in the retention test. The maximum entry latencies al-
lowed in the training and retention sessions were 60 and 180 s re-
spectively.
Spatial reference memory in the Morris water maze. Spatial learn-
ing was assessed in an open-field water maze (Morris 1984), con-
sisting of a large, circular, transparent tank (diameter 1.5 m; depth
0.6 m) containing water at 24±1°C at a depth of 0.3 m. The rats’
task was to escape from the water by locating a hidden, transparent
escape platform (diameter 14 cm) submerged 1.5 cm below the
surface of the water. The water was made partially opaque by the
addition of 3 l semi-skimmed milk that prevented the animals from
seeing the platform. The pool was located on the floor in the cen-
tre of an acoustically insulated room (4×4 m) kept at a constant
temperature (24±1°C). Illumination inside the room, containing
various prominent cues, was 60 lux. The swim paths taken by the
animals in the pool were monitored by a video camera mounted in
the ceiling. The resulting video signal was relayed to a video
recorder.
All rats were trained to find a hidden escape platform, in a fixed
location. They received 5 days of training with a ten-trial block per
day. The platform was located in the centre of a chosen quadrant of
the pool. The rats were placed into the pool facing the side wall at
a position chosen randomly (the start points were chosen ran-
domly, always starting from the external edge) across trials and al-
lowed to swim until they found the platform, or for a maximum of
60 s. Any rat that failed to find the platform in time was guided to
its location by the experimenter. The rats were then allowed to re-
main on the platform for 20 s. They were then removed gently
from the platform and placed for 20 s in a cage on the floor of the
same room before commencing the next trial. On completion of
behavioural testing the rats were returned to their home cages
where they were warmed briefly under a heating lamp. Then, 96 h
after the last acquisition training, the rats were again subjected to
the same behavioural procedure (retention/retraining test). The la-
tencies for reaching the platform were recorded blindly using a
stopwatch. Data reported for each day’s training were the means of
ten trials.
Pentobarbitone-induced hypnosis. After mice had been given pen-
tobarbitone sodium (60 mg kg–1 i.p.), the loss of the righting reflex
was measured. The duration of hypnosis was taken as the time re-
quired to regain the righting reflex. Mice were pretreated with
DM235 (0.1–1 mg kg–1 i.p.), or piracetam (30 mg kg–1 i.p.) 20 or
30 min respectively before the injection of pentobarbitone.
Hole board test. The hole board test utilizes a 40-cm square plane
with 16 flush-mounted cylindrical holes (diameter 3 cm) distrib-
uted 4-by-4 in an equidistant, grid-like manner. The plane of the
hole board is made of black metal; the separation of the holes from
each other is 5.5 cm; the distance of the outermost holes from the
edge of the board is 5 cm. The mice were placed in the centre of
the board one by one and left to move about freely for a period of
5 min each. Two photoelectric beams, crossing the plane from
mid-point to mid-point of opposite sides, thus dividing the plane
into four equal quadrants, automatically signalled the movement of
the animals on the surface of the plane. Miniature photoelectric
cells, in each of the 16 holes, recorded the exploration of the holes
(head plunging activity) by the mice.
Rota-rod test. The apparatus consists of a base platform and a ro-
tating rod of 3 cm diameter with a non-skid surface made of black
plastic. The rod was placed at a height of 15 cm from the base. The
rod, 30 cm in length, was divided into five equal sections by six
disks, thus allowing up to five mice to be tested simultaneously,
with a rod rotation speed of 16 rpm. The integrity of motor coordi-
nation was assessed as the number of falls from the rod in 30 s, ac-
cording to Vaught et al. (1985). Performance time was measured
before and 15, 30 and 45 min after intraperitoneal administration
of the drugs.
Spontaneous activity meter (Animex). Locomotor activity in rats
was quantified using an Animex activity meter Type S (LKB,
Farad, Sweden) set to maximum sensitivity. Every movement of
rats, which were placed on the top of the Animex activity meter,
produced a signal due to variation in inductance and capacity of
the apparatus resonance circuit. Signals were converted automati-
cally to numbers. On the day of the experiment the rats were
treated and the cage, containing three rats, then put on the measur-
ing platform. Activity counts were made for 5 min at 15-min inter-
vals for 45 min (total of three sessions) starting immediately after
injection of the drug. Because of the arbitrary scale adopted to
quantify movements, drug-treated rats were always compared with
saline-treated ones.
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Fig.1 DM235 (sunifiram): 
1-benzoyl-4-propionylpiper-
azine
Drugs. The following drugs were used: DM235 (sunifiram) pre-
pared in the Department of Pharmaceutical Sciences of University
of the Florence according to the method described by Manetti et al.
(2000a); scopolamine hydrobromide, piracetam, (±)-baclofen
(Sigma); mecamylamine hydrochloride, clonidine hydrochloride,
(±)-rolipram (RBI); nicotine hydrogentartrate (Fluka); aniracetam
(A. Menarini Industrie Farmaceutiche Riunite); pentobarbitone
(Sagatal). Drugs were dissolved in isotonic (NaCl 0.9%) saline so-
lution, for i.p. injection, or dispersed in sodium carboxymethyl cel-
lulose 1%, for p.o. administration, immediately before use. Drug
concentrations were such that the necessary dose could be admin-
istered in volumes of 10 ml kg–1 (i.p. or p.o.) for mice and 3 ml kg–1
(i.p.) for rats.
Pharmacological treatments. For memory disruption in the pas-
sive avoidance test, mice were injected i.p. with amnesic drugs im-
mediately after termination of the training trial (scopolamine, bac-
lofen, mecamylamine) or 60 min before the training trial (cloni-
dine). DM235, piracetam, aniracetam, rolipram and nicotine were
injected 20 (i.p.) or 30 (p.o.) min before the training trial. In the
water maze experiments, rats were injected i.p. with DM235
and/or scopolamine 20 min before each daily acquisition training.
The day of the retention/retraining rats were all injected i.p. with
saline solution 20 min before the test.
Statistical analysis. All experimental results are given as means±
SEM. Analysis of variance (ANOVA), followed by Fisher’s pro-
tected least significant difference (PLSD) procedure for post-hoc
comparison, was used to verify significance of differences be-
tween means in mouse behavioural data. Mixed ANOVAs with
pharmacological treatments as a between-subjects variable and the
training days as a within-subjects variable and Newman-Keuls mul-
tiple comparisons test were used for rat behavioural experiments.
Data were analysed using StatView software on a Macintosh com-
puter. P<0.05 (2-tailed) was considered significant.
Results
In the passive avoidance test in mice, pretreatment with
DM235 prevented the amnesia induced by the administra-
tion of the antimuscarinic drug scopolamine (1.5 mg kg–1
i.p.) after i.p. (0.001–0.1 mg kg–1, Fig.2A) or p.o.
(0.01–0.1 mg kg–1, Fig.2B) injection. The maximal anti-
amnesic effect of DM235 was obtained with the dose of
0.001 mg kg–1 i.p. and maintained up to 0.1 mg kg–1 i.p.
The DM235-induced antiamnesic effect was of the same
intensity as that exerted by the well-known nootropic
drugs piracetam (30 mg kg–1 i.p.), aniracetam (100 mg
kg–1 p.o.) or rolipram (30 mg kg–1 p.o.) (Fig.2A and B).
Lower doses of DM235 (0.0001 mg kg–1 i.p.), piracetam
(10 mg kg–1 i.p.) aniracetam (50 mg kg–1 p.o.) or rolipram
(10 mg kg–1 p.o.) (Fig.2A and B) were devoid of any
ameliorative effect on scopolamine-induced amnesia. At
0.1 mg kg–1 i.p., the entrance latency value of the DM235-
treated group in the retention session was comparable to
that produced by control mice.
The administration of DM235 (0.01–0.1 mg kg–1 i.p.)
antagonized the memory disruption produced by mecamyl-
amine (20 mg kg–1 i.p.), similarly to the antiamnesic ef-
fect produced by nicotine (5 mg kg–1 i.p.) and piracetam
(30 mg kg–1 i.p.). DM235 at 0.001 mg kg–1 i.p. was com-
pletely ineffective (Fig.3).
DM235 at (0.01 and 0.1 mg kg–1 i.p.) also prevented
the amnesia induced by baclofen (2 mg kg–1 i.p.), but at
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Fig.2 Dose/response curve for DM 235 administered either i.p. in
comparison with piracetam (A) or orally in comparison with
aniracetam and rolipram (B) on amnesia induced by scopolamine
(1.5 mg kg–1 i.p.) in a passive avoidance test in mice. DM235,
piracetam, aniracetam and rolipram were administered 20 min
(i.p.) or 30 min (p.o.) before the training session while scopol-
amine was injected immediately after. The numbers in the columns
indicate the numbers of mice tested. **P<0.01, *P<0.05 vs. scopol-
amine-treated mice
Fig.3 Dose/response curve for DM235 (administered i.p.) in
comparison with nicotine and piracetam on amnesia induced by
mecamylamine (20 mg kg–1 i.p.) in a passive avoidance test in
mice. DM235, nicotine and piracetam were administered 20 min
before training session while mecamylamine was injected immedi-
ately after. **P<0.01; *P<0.05 vs. mecamylamine-treated mice
0.001 mg kg–1 i.p. DM235 was devoid of any effect (Fig. 4).
The prevention of memory impairment by DM235 was
comparable to the effect of piracetam (30 mg kg–1 i.p.,
Fig.4).
The memory impairment induced by clonidine
(0.125 mg kg–1 i.p.) in the mouse passive avoidance test
was prevented by DM235 (0.01–0.1 mg kg–1 i.p.) and
piracetam (30 mg kg–1 i.p.), used as reference drug
(Fig.5). A tenfold lower dose of DM235 was ineffective
(Fig.5).
At active doses DM235 did not enhance the entrance la-
tency in normal mice in comparison with the control group
(Fig.2). Furthermore, there were no differences observed
in the various entrance latencies of every group in the train-
ing session of the passive avoidance test (Figs. 2, 3, 4, 5).
In the Morris water maze test, all rats swam well in the
pool and showed no evidence of sensorimotor impair-
ment. As training proceeded, the rats spent progressively
less time at, or near, the side walls and learned to use the
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Fig.4 Dose/response curve for DM235 (administered i.p.) in com-
parison with piracetam on amnesia induced by baclofen in a pas-
sive avoidance test in mice. DM235 and piracetam were adminis-
tered 20 min before training session while baclofen (2 mg kg–1 i.p.)
was injected immediately after. **P<0.01; *P<0.05 vs. baclofen-
treated mice
Fig.5 Dose/response curve of DM235 (i.p.) in comparison with
piracetam on amnesia induced by clonidine in a passive avoidance
test in mice. DM235 and piracetam were administered 20 min be-
fore training session while clonidine (0.125 mg kg–1 i.p.) was in-
jected 60 min before test. **P<0.01 vs. clonidine-treated mice
Fig.6A,B The effect of DM235 (sunifiram) (0.1 mg kg–1 i.p.) on
spatial reference memory in rats in the Morris water maze test. 
A Effect of DM235 on scopolamine (0.8 mg kg–1 i.p.)-induced im-
pairment of acquisition. Task acquisition is reflected as a decrease
in escape latency. Means±SEM, *P<0.05 vs. saline-treated rats. 
B Effect of DM235 on scopolamine-induced impairment on the re-
tention-retraining day. Means±SEM, *P<0.05 vs. saline-treated
rats
platform as a means of escape from the water. Conse-
quently, all animals showed a reduction in escape laten-
cies and path lengths with training. A significant reduc-
tion of the average escape latencies in the daily blocks
during the 5 days of water maze acquisition and the reten-
tion/retraining was revealed (Fig.6A). There was also a
significant main effect of treatment. The scopolamine-
treated rats showed longer latencies and path lengths be-
fore finding the platform than the other three groups of
rats on day 5 (Fig.6A) and on retention/retraining day
(Fig.6B). DM235 (0.1 mg kg–1 i.p.) reversed the memory
impairment induced by scopolamine on both acquisition
and retention/retraining days, whereas, when adminis-
tered alone, it did not ameliorate unimpaired memory
processes (Fig.6). There were no differences between the
escape latencies of the last day of acquisition and the re-
tention/retraining test (Fig.6).
DM235 (1 mg kg–1 i.p.) significantly reduced the total
sleeping time (22.1±3.4 min) induced by 60 mg kg–1 i.p.
pentobarbital (27.7±3.3 min), similar to the effect induced
by 30 mg kg–1 i.p. piracetam (12.5±5.3 min), whereas the
dose of 0.1 mg kg–1 i.p. was ineffective. At the same doses
both drugs did not modify the induction time of hypnosis
(control 3.9±1.8; DM235: 4.3±2.0; piracetam: 4.5±2.1 min).
It should be noted that DM235 elicited its antiamnesic
effect without changing the animals’ gross behaviour. No
modification of motor coordination was revealed by the
rota-rod test in the mouse. DM235 (0.1–10 mg kg–1 i.p.)
did not modify the number of falls from the rotating rod in
comparison with saline-treated mice (Table 1). Further-
more, the spontaneous mobility of mice and rats, as re-
vealed by the hole board test (data not shown) and the
Animex apparatus (Table 2) respectively was unmodified
by DM235 (0.1 mg kg–1 i.p.) in comparison with saline-
treated animals.
Discussion
The present results describe the effects observed with
DM235 on experimentally impaired memory processes in
mice and rats. DM235 ameliorates cognitive processes by
preventing pharmacologically-induced amnesia in the
mouse passive avoidance and rat Morris water maze tests.
Previous results have also demonstrated a procognitive
activity of that DM235 in a social learning task in rats
(Manetti et al. 2000a).
DM235 prevented amnesia induced by the antimus-
carinic drug scopolamine after i.p. and p.o. administration
and by the nicotinic antagonist mecamylamine in the
mouse passive avoidance test. Furthermore, DM235 re-
versed the impairment of acquisition and retention/re-
training produced by scopolamine in the Morris water
maze test in rats. The lack of difference in the escape la-
tencies between the last day of acquisition and the reten-
tion/retraining test excluded the possibility of induction of
state-dependent effects (McGaugh 1989; Overton 1991).
These results are in agreement with data obtained after ad-
ministration of nootropic drugs. Pyrrolidone derivatives
not only reverse the amnesia induced by impairment of
the cholinergic system in a passive avoidance task (Ver-
loes et al. 1988), but nootropic compounds, such as ne-
firacetam and oxiracetam, also counteract cognitive deficits
in a Morris water maze paradigm (Pitsikas and Algeri
1992; Fordyce et al. 1995; DeFord et al. 2001).
That stimulation of the cholinergic system improves
cognitive processes has long been observed (Deutsch
1971; Bartus et al. 1982; Coyle 1995). Conversely, block-
ade of the cholinergic system disrupts memory functions.
The administration of scopolamine, an unselective mus-
carinic ACh receptor antagonist, impairs learning and
memory in humans (Frumier et al. 1976) and animals
(Levin and Bowman 1986). Mice or rats treated with the
M1 selective antagonists pirenzepine and dicyclomine
show impaired memory processes in various paradigms
(Caulfield 1993; Sala et al. 1991; Ghelardini et al. 1997).
Furthermore, the administration of a nicotinic ACh recep-
tor antagonist, such as mecamylamine, dose-dependently
impairs performance in passive avoidance tests (Elrod and
Buccafusco 1991).
Microdialysis studies have shown that DM235 in-
creases ACh release from the rat parietal cortex (Manetti
et al. 2000b), a cerebral structure involved in the modula-
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Table 1 Lack of effect of
DM-235 in comparison with
piracetam in the mouse rota
rod test. Means±SEM; n=10
mice
Dose Number of falls (30 s)
Before After treatment
treatment
15 min 30 min 45 min
Saline 10 ml kg–1 i.p. 3.4+0.4 2.2±0.3 1.7±0.2 1.1±0.2
DM235 0.1 mg kg–1 i.p. 3.7±0.5 2.5±0.4 1.5±0.4 1.3±0.3
DM235 1.0 mg kg–1 i.p. 3.5+0.3 1.9±0.4 1.3±0.3 1.2±03
DM235 10 mg kg–1 i.p. 3.8±0.5 2.3±0.4 1.5±03 0.8±0.2
Piracetam 30 mg kg–1 i.p. 3.6±0.4 2.6±0.4 1.0+0.2 1.0+0.2
Table 2 Lack of effect of DM-235 in the rat Animex test. Means±
SEM; n=10 rats
Dose Number of counts
After treatment
15 min 30 min 45 min
Saline 10 ml kg–1 i.p. 688±45 112±19 37±13
DM235 0.1mg kg–1 i.p. 691±50 125±21 45±10
tion of cognitive processes (Bartus et al. 1982). Therefore,
the potentiation of the cholinergic system by DM235
could make it able to prevent amnesia induced by an an-
timuscarinic drug as well as by the administration of a
nicotinic antagonist. Extensive study of the modes of ac-
tion of the pyrrolidone derivatives has revealed various
pharmacological effects, with striking differences be-
tween drugs suggesting that no single predominant mode
of action is shared by the whole class of drugs. Most,
however, influence cholinergic function. Acetylcholine
production and turnover are stimulated by most pyrroli-
done derivatives but with varying actions at both mus-
carinic and nicotinic receptors. In particular, piracetam
might alter presynaptic cholinergic function, possibly by
enhancing high-affinity neuronal uptake of choline (Pe-
data et al. 1984), but these data are controversial (Franklin
et al. 1986). Pilch and Müller (1988) have shown that
piracetam elevates muscarinic receptor density in the
frontal cortex of aged but not of young mice. Increased
acetylcholine release has been demonstrated for piracetam
(Hitzenberger et al. 1998) and aniracetam increases acetyl-
choline content in the hippocampus and cerebral cortex
(Toide 1989).
Affinity for central receptors might explain the poten-
tiation of the endogenous cholinergic system by DM235.
In binding studies, however, DM235 (10–6 M) showed
affinity for neither muscarinic and nicotinic receptors, nor
for the other most important central receptors (data not
shown). A lack of receptor affinity is also a characteristic
feature of the nootropic compounds. These drugs, with the
exception of nefiracetam, which shows high affinity for
the GABAA receptors, do not seem to act at any well-char-
acterized receptor system (Gouliaev and Senning 1994).
Indeed, as already postulated for nootropic compounds
(Mondadori et al. 1991; Muller et al. 1999), the effects of
DM235 on the cholinergic system might be secondary.
Amnesia can also be obtained by modulating neuro-
transmitter systems other than the cholinergic system.
GABA is the main inhibitory neurotransmitter in the brain
and plays an important role in learning and memory. The
activation of GABAA and GABAB receptors reportedly
impairs memory performance (Jerusalinsky et al. 1994;
Swartzwelder et al. 1987). Cognitive processes, including
learning and memory, can be ameliorated by GABAB re-
ceptor antagonists (Mondadori et al. 1992). α2-Agonists
also exert a variety of effects on the central nervous sys-
tem. Central depression usually accompanies therapeutic
doses of α2-agonists and impairment of cognitive func-
tions is also observed (Voronina et al. 1991; Genzoka-Pa-
pazova et al. 1997).
DM235, even in the absence of any interaction with
GABAB or α2-adrenoceptors, prevented the amnesia in-
duced by baclofen and clonidine. Thus, DM235 counter-
acts amnesia not only induced by anticholinergic drugs,
but also that induced of blockade of the cholinergic sys-
tem. The capability for reversing the amnesia induced by
activation of GABAB receptors is also observed with fa-
soracetam (Ogasawara et al. 1999). The involvement of
the GABAergic system in the mechanism of action of
pyrrolidone derivatives has also been postulated. The
chemical similarity between GABA and pyrrolidones has
prompted many studies on the role of the GABAergic sys-
tem in the amelioration of memory processes by nootropic
drugs. However, with the sole exception of fasoracetam,
which up-regulates GABAB receptors (Ogasawara et al.
1999), few of these drugs have any substantial action at
GABA receptor sites (Gouliaev and Senning 1994).
DM235 did not show any procognitive activity in the
passive avoidance and Morris water maze tests when
given alone. However, an improvement in cognition of
young animals that have no memory impairment is diffi-
cult to demonstrate. As a matter of fact, not only DM235
but also well-known nootropic drugs such as piracetam,
aniracetam, nefiracetam and oxiracetam, or cholinomi-
metics such as physostigmine and oxotremorine, do not
facilitate memory in unamnesic animals (Pitsikas and Al-
geri 1992; Gouliaev and Senning 1994; Coyle 1995;
Fordyce et al. 1995; DeFord et al. 2001). In the first ses-
sion, neither the latency for entering the dark compart-
ment of the light-dark box in the passive avoidance test
nor the escape latency in the Morris water maze test were
modified by the administration of DM235.
The ability of nootropics to reduce sleeping time has
been observed in humans. Hollister (1985) has reported
that piracetam increases waking hours in elderly. This
waking effect would be beneficial for patients in whom
senile dementia is associated with persistent sleepiness.
DM235 reduced the total sleeping time induced by pento-
barbitone without modifying the induction time of hypno-
sis. This effect was comparable to that exerted by pirac-
etam, even though weaker than that produced by the
nootropic compound and present only at high doses.
The amelioration of memory process induced by
DM235 occurred without any side effects. DM235, at the
highest effective doses, neither impaired motor coordina-
tion, as revealed by the rota-rod test, nor modified sponta-
neous motility, as indicated by the Animex apparatus and
the hole board test. Furthermore, DM235 at a dose 1,000
times higher than the minimal effective dose, is still de-
void of any alteration of behavioural parameters.
The present results provide evidence that DM235 is a
new antiamnesic compound for which membership of the
class of nootropic drugs can be supposed. Indeed, DM235,
even though not a pyrrolidone derivative, shows a high
degree of structural similarity with piracetam (Manetti et
al. 2000a) and also exhibits a pharmacological profile
comparable to that of nootropics. DM235 is, in fact, en-
dowed with the main pharmacological properties of pirac-
etam-like compounds: facilitation of memory processes,
lack of toxicity and side effects and a lack of affinity to-
wards the most important central receptors. DM235 dif-
fers from pyrrolidone derivatives in its potency. Even
though it exerts the same pharmacological effects, DM235
is at least 100 times more potent than the most active
nootropic drugs such as oxiracetam, nefiracetam, etirac-
etam, aniracetam (Gouliaev and Senning 1994).
In conclusion, these results indicate that DM235 is a
novel cognition enhancer, chemically and pharmacologi-
424
cally closely related to the piracetam-like compounds but
endowed with higher potency. These observations, to-
gether with the lack of side effects at a dose 1,000 times
higher than the minimally effective dose, suggest that
DM235 may be a promising compound for the treatment
of human cognitive deficits.
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